Nuclear Medicine Communications SCIE

國際簡稱：NUCL MED COMMUN 參考譯名：核醫(yī)學通訊

主要研究方向：醫(yī)學-核醫(yī)學非預警期刊審稿周期：一般,3-8周

《核醫(yī)學通訊》(Nuclear Medicine Communications)是一本由Lippincott Williams and Wilkins Ltd.出版的以醫(yī)學-核醫(yī)學為研究特色的國際期刊，發(fā)表該領域相關的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領域相關理論、實踐和應用學科的最新發(fā)現(xiàn)，旨在促進該學科領域科學信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預警名單。

4區(qū) 中科院分區(qū)
Q3 JCR分區(qū)
138 年發(fā)文量
1.3 IF影響因子
未開放 是否OA
67 H-index
1980 創(chuàng)刊年份
Monthly 出版周期
English 出版語言

Nuclear Medicine Communications, the official journal of the British Nuclear Medicine Society, is a rapid communications journal covering nuclear medicine and molecular imaging with radionuclides, and the basic supporting sciences. As well as clinical research and commentary, manuscripts describing research on preclinical and basic sciences (radiochemistry, radiopharmacy, radiobiology, radiopharmacology, medical physics, computing and engineering, and technical and nursing professions involved in delivering nuclear medicine services) are welcomed, as the journal is intended to be of interest internationally to all members of the many medical and non-medical disciplines involved in nuclear medicine. In addition to papers reporting original studies, frankly written editorials and topical reviews are a regular feature of the journal.

[ 查看全部 ]

投稿咨詢加急咨詢

Nuclear Medicine Communications期刊信息

ISSN：0143-3636
出版語言：English
是否OA：未開放
E-ISSN：1473-5628
出版地區(qū)：UNITED STATES
是否預警：否
出版商：Lippincott Williams and Wilkins Ltd.
出版周期：Monthly
創(chuàng)刊時間：1980
開源占比：0.1027
Gold OA文章占比：13.60%
OA被引用占比：0.0599...
出版國人文章占比：0.12
出版撤稿占比：0
研究類文章占比：89.86%

Nuclear Medicine Communications CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

2.2

0.374

0.419

學科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Radiology, Nuclear Medicine and Imaging	Q3	206 / 333	38%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據(jù)是期刊最近4年（含計算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻數(shù)。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻數(shù)量注：文獻類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Nuclear Medicine Communications中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫(yī)學	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學	4區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫(yī)學	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學	4區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫(yī)學	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學	4區(qū)

中科院 2021年12月基礎版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫(yī)學	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學	4區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫(yī)學	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學	4區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫(yī)學	4區(qū)	RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核醫(yī)學	4區(qū)

Nuclear Medicine Communications JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING	SCIE	Q3	138 / 204	32.6%

按JCI指標學科分區(qū)	收錄子集	分區(qū)	排名	百分位
學科：RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING	SCIE	Q3	139 / 204	32.11%

Nuclear Medicine Communications歷年數(shù)據(jù)統(tǒng)計

影響因子

中科院分區(qū)

Nuclear Medicine Communications中國學者發(fā)文選摘

1、Value of Tc-99m-MIBI SPECT/CT in the localization of recurrent lesions in patients with suspected recurrent parathyroid carcinoma
Author: Guo, Yue-Hong; Huang, Jing-Wei; Wang, Ying; Lu, Ruigang; Yang, Min-Fu

Journal: NUCLEAR MEDICINE COMMUNICATIONS. 2023; Vol. 44, Issue 1, pp. 18-26. DOI: 10.1097/MNM.0000000000001641
2、A retrospective study of clinical features and prognosis of patients with Graves' disease and ophthalmopathy
Author: Rui, Zhong Ying; Yin, Xue; Wang, Xuan; Shen, Jie; Zheng, Wei

Journal: NUCLEAR MEDICINE COMMUNICATIONS. 2023; Vol. 44, Issue 2, pp. 137-141. DOI: 10.1097/MNM.0000000000001649
3、A novel urokinase plasminogen activator receptor-targeted peptide-based probe for in-vivo molecular imaging of glioblastoma
Author: Han, Yunfeng; Tu, Le; Zhang, Yongxue; Xu, Liying; Sun, Ziyan

Journal: NUCLEAR MEDICINE COMMUNICATIONS. 2023; Vol. 44, Issue 2, pp. 142-149. DOI: 10.1097/MNM.0000000000001644
4、Utility of pre-treatment F-18-fluorodeoxyglucose PET radiomic analysis in assessing nodal involvement in cervical cancer
Author: Chan, Kit Chi; Perucho, Jose A. U.; Subramaniam, Rathan M.; Lee, Elaine Y. P.

Journal: NUCLEAR MEDICINE COMMUNICATIONS. 2023; Vol. 44, Issue 5, pp. 375-380. DOI: 10.1097/MNM.0000000000001672
5、Comparison of Ga-68-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies
Author: Zheng, Wenlu; Liu, Lin; Feng, Yue; Wang, Li; Chen, Yue

Journal: NUCLEAR MEDICINE COMMUNICATIONS. 2023; Vol. 44, Issue 3, pp. 194-203. DOI: 10.1097/MNM.0000000000001653
6、Correlations between glucose metabolism of bone marrow on F-18-fluoro-D-glucose PET/computed tomography and hematopoietic cell populations in autoimmune diseases
Author: Zhang, Tong; Zhang, Jifeng; Wang, Hongjia; Li, Ping

Journal: NUCLEAR MEDICINE COMMUNICATIONS. 2023; Vol. 44, Issue 3, pp. 212-218. DOI: 10.1097/MNM.0000000000001657
7、Using eZIS of SPECT to evaluate the therapeutic effect of carotid endarterectomy
Author: Zhang, Zhiting; Sun, Danyang; Wang, Xuan; Li, Wei

Journal: NUCLEAR MEDICINE COMMUNICATIONS. 2023; Vol. 44, Issue 4, pp. 252-258. DOI: 10.1097/MNM.0000000000001662
8、Role of 18F-fluorodeoxyglucose PET/computed tomography in the diagnosis and treatment response assessment of primary bone lymphoma
Author: Pu, Yongzhu; Wang, Chun; Xie, Ran; Zhao, Sheng; Li, Kun; Yang, Conghui; Li, Jindan; Xiang, Anshi; Wang, Yasong; Chen, Long; Sun, Hua

Journal: NUCLEAR MEDICINE COMMUNICATIONS. 2023; Vol. 44, Issue 4, pp. 318-329. DOI: 10.1097/MNM.0000000000001668